Experimental Treatments for Myasthenia Gravis

Batoclimab is an experimental antibody therapy being developed for the treatment of a number of autoimmune diseases, including generalized MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to lower the levels of MG-causing antibodies in order to ease disease severity.

CABA-201 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a one-time intravenous, or into-the-bloodstream, infusion after a course of chemotherapy, the therapy is designed to target disease-driving immune B-cells to potentially reduce MG severity.

Cladribine is a short-course oral therapy being developed for generalized MG. Administered as oral capsules, it’s designed to lower the levels of the immune cells that drive inflammatory attacks in MG.

Firdapse (amifampridine) is being developed to treat muscle weakness in a rare type of MG called MuSK-MG. It is currently in Phase 3 trials in these patients.

Gefurulimab is an experimental therapy being developed for the treatment of generalized MG. Administered in the form of subcutaneous, or under-the-skin, injections that can be self-administered, it is designed to block the activation of the complement system, a part of the immune system that’s thought to be involved in the disease’s autoimmune attacks.

Inebilizumab is an antibody-based therapy being developed for the treatment of MG. Administered via intravenous, or into-the-vein, infusions every six months, the therapy is expected to reduce the levels of certain immune cells that drive MG and ease disease symptoms.

KYV-101 is an investigational CAR T-cell therapy that’s being developed for the treatment of MG. Administered via a single infusion into the bloodstream, or intravenously, after a short course of chemotherapy, it is designed to lower the levels of immune B-cells and potentially ease disease severity.

Myasterix (CV-MG01) is an investigational therapeutic vaccine intended to alleviate the symptoms of myasthenia gravis. It was most recently tested in a Phase 1 trial. A Phase 2/3 trial was planned but was withdrawn due to issues with recruitment.

Nipocalimab is an experimental antibody therapy being developed for the treatment of a number of autoimmune diseases, including generalized MG. The therapy, administered via into-the-vein (intravenous) infusions, is designed to lower the levels of MG-causing antibodies in order to ease disease severity.

NMD670 is an investigational oral therapy being developed for MG and a number of rare diseases. The therapy, administered twice daily in the form of oral tablets, is designed to improve nerve-muscle communication and restore muscle function.

A combination of the antibody therapy pozelimab and an RNA-based therapy called cemdisiran is being developed for the treatment of MG. Administered in the form of monthly subcutaneous, or under-the-skin, injections, the combination is designed to block the activation of the complement system, a part of the immune system thought to be involved in the disease’s autoimmune attacks.

Rituximab is designed to target a protein called CD-20 that is present in B-cells, which are harmful in MG. It is currently in Phase 3 trials.

Subcutaneous immunoglobulin, a new formulation of immunoglobulin, is given as an under-the-skin injection using a portable infusion pump. It is under investigation for MG treatment in Phase 3 trials.

Telitacicept is an investigational B-cell targeting therapy being developed as a potential treatment for MG. The therapy, administered in the form of under-the-skin (subcutaneous) injections, is designed to reduce the activity of immune B-cells that drive MG.